US 12331036
Heterocyclic RIP1 kinase inhibitors
granted A61KA61K31/553A61P
Quick answer
US patent 12331036 (Heterocyclic RIP1 kinase inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/553, A61P, A61P29/00, A61P37/00